Skip to main content
Log in

Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma

  • Experimental Oncology
  • Published:
British Journal of Cancer Submit manuscript

Abstract

In a multicentre study, 83 patients with advanced and previously uniformly treated multiple myeloma (MM) were randomised between cyclophosphamide (600 mg m-2) and epirubicin (70 mg m-2), administered every 3 weeks for three courses and both associated with prednisone and interferon-alpha2b. Both regimens were administered on an outpatient basis and had low haematological toxicity. Clinical results were similar. Overall response rate (43%) and median response and survival (5.9 and 14.1 months respectively) compare well with those obtained with more aggressive chemotherapy schedules.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Consortia

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brugnatelli, S., Riccardi, A., Ucci, G. et al. Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. Br J Cancer 73, 794–797 (1996). https://doi.org/10.1038/bjc.1996.138

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1996.138

  • Springer Nature Limited

Navigation